A5007258959- Cystic Fibrosis Research Advances
- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Resistance in Bacteria
- Pneumonia and Respiratory Infections
- Dialysis and Renal Disease Management
- Diabetes Treatment and Management
- Pharmaceutical studies and practices
- Chronic Kidney Disease and Diabetes
- Hemodynamic Monitoring and Therapy
- Plant Pathogenic Bacteria Studies
- Inhalation and Respiratory Drug Delivery
- Neonatal Respiratory Health Research
- Analytical Methods in Pharmaceuticals
- Employment and Welfare Studies
- Health disparities and outcomes
- Healthcare Policy and Management
- Geriatric Care and Nursing Homes
- Pediatric health and respiratory diseases
- Potassium and Related Disorders
- Esophageal and GI Pathology
- Renal Diseases and Glomerulopathies
- Bacterial biofilms and quorum sensing
- Health Systems, Economic Evaluations, Quality of Life
- Workplace Health and Well-being
University Medical Center Groningen
2024-2025
University of Groningen
2024-2025
Maastricht University
2024
Maastricht University Medical Centre
2024
Vrije Universiteit Amsterdam
1996-1997
Apotheek Haagse Ziekenhuizen
1994-1996
Erasmus University Rotterdam
1996
Rijnstate Hospital
1996
Royal Brompton Hospital
1995
Leiden University
1994
Aerosol administration of antipseudomonal antibiotics is commonly used in cystic fibrosis. However, its contribution to the improvement lung function, infection and quality life not well-established. All articles published from 1965 until present time concerning inhalation fibrosis were collected by computerized literature search analysed. Effective aerosol delivery compromised nebulizers with limited capacity produce particles respirable range. Twelve studies maintenance treatment...
Abstract Background Several clinical trials have shown beneficial effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on kidney disease progression and cardiovascular morbidity mortality in patients with chronic (CKD) without type diabetes mellitus. However, some subgroups CKD been excluded from participation these trials, such as severely impaired function, dialysis, transplant recipients. Methods The Renal Lifecycle trial (NCT05374291) is a pragmatic, international, multicenter,...
This study was performed to determine the clinical pharmacokinetics of tobramycin in six patients with cystic fibrosis (CF) after inhalation 600 mg. Tobramycin administered an ultrasonic nebulizer (WISTO SENIOR). Blood and urine were sampled until 24 h inhalation. Maximum levels serum varied from 0.19 2.57 mg/liter (mean 1.27 mg/liter; standard deviation, 1.07 mg/liter). Systemic availability (calculated urinary output) ranged 6.0 27.4% (mean, 17.5%; 8.8%). The results illustrate that,...
BACKGROUND: Research on the cost of care patients with cystic fibrosis is scarce. The aim this study was to estimate costs using age-specific medical consumption from real patient data. METHODS: in Netherlands 1991 estimated a survey records and questionnaire. A distinction made between hospital care, non-hospital medication, home care. Costs per year were obtained by multiplying yearly amount unit. RESULTS: On average annual 10,908 pounds (hospital 42%, medication 37%, 20%). Netherlands,...
Acute exacerbations of Pseudomonas aeruginosa lung infections were treated with ceftazidime (CTZ) by continuous infusion (CI) in eight adult cystic fibrosis (CF) patients. CTZ pharmacokinetics studied after a single dose and during CI (100 mg/kg/24 h) CADD-PLUS pump at home for 3 weeks. Individual pharmacokinetic parameters single-dose administration half-life (t1/2β) 1.90 ± 0.85 h (mean SD), volume distribution (VS) 0.28 0.08 L/kg, total body clearance (CL) 0.152 0.014 L/h/kg. CL was 0.147...
Abstract Background Patients undergoing dialysis have an impaired health-related quality of life (HRQOL). There are conflicting data from small series on whether patient-related factors such as educational level impact experienced HRQOL. The aim this study was to investigate the association between and HRQOL in patients. Methods In a single-center retrospective cross-sectional measured using Kidney Disease Quality Life Short Form-36 (KDQOL-SF36) prevalent chronic Educational categorized into...
Postinfusion data obtained from 17 patients with cystic fibrosis participating in two clinical trials were used to develop population models for ceftazidime pharmacokinetics during continuous infusion. Determinant (D)-optimal sampling strategy (OSS) was evaluate the benefits of merging four maximally informative times modeling. Full and sparse D-optimal sets analyzed nonparametric expectation maximization (NPEM) algorithm compared model by traditional standard two-stage approach. Individual...
Cystic fibrosis (CF) causes a relatively high medical consumption. A large part of the treatment takes place at home. Because data regarding nonhospital care are lacking, we wished to determine costs patients with CF outside hospital. questionnaire was sent 73 from two Dutch hospitals (response rate 64%, 14 children and 33 adults). Average consumption average per patient year were calculated for adults six categories: care; domestic help; diet; travelling because CF; medication; devices...
Clinical pharmacokinetic data of intravenously administered tobramycin in 34 patients with cystic fibrosis (CF) were correlated patient parameters. Patients began therapy 10 mg/kg/day three divided doses. Peak and trough serum concentrations measured. Tobramycin dose was adjusted to a 30 min postdose peak mg/L predose 1 mg/L. Pharmacokinetic calculated according one-compartment open model clinical data. half-life total body clearance did not correlate age, actual weight, lean mass, height,...
Assessment of renal function and relating this parameter to amino-glycoside clearance is important for an appropriate individualization dosage regimens in patients with impaired function. However, it has been suggested that cystic fibrosis (CF), creatinine (CrCl) not a good predictor tobramycin because lack correlation. The aim study was investigate the correlation between measured CrCl. In addition, most pharmacokinetic computer models use priori relationship CrCl elimination rate constant...
The predictive performance of a dosage calculation method for the optimization tobramycin therapy was studied retrospectively in 29 patients with cystic fibrosis. based on linear one-compartment open model. It used peak and trough serum concentrations aminoglycoside. Bias concentration 0.20 mg/L precision 1.2 mg/L. −0.06 0.33 results were clinically satisfactory. Comparison previously published other methods showed that at least as good.
The predictive performance of a new algorithm to calculate the initial daily dose tobramycin in patients with cystic fibrosis (CF) was prospectively evaluated. Twenty-six CF (15 men, 11 women, 18-45 years age) an acute exacerbation their chronic pulmonary infection were treated intravenous tobramycin. calculated previously presented algorithm. This derived from correlation analysis performed on adjusted guided by determination serum concentrations: (mg three times daily) = 90 + 2.13 x LBM...
Abstract Background and Aims Patients undergoing dialysis have an impaired health-related quality of life (HRQOL). There are conflicting data from small series whether patient-related factors such as educational level impact on experienced HRQOL. The aim this study was to investigate the association between HRQOL in patients. Method In a single-center retrospective cross-sectional measured using Kidney Disease Quality Life Short Form-36 (KDQOL-SF36) prevalent chronic Educational categorized...
The indication for sodium-glucose cotransporter 2 (SGLT2) inhibitors to slow the progression of kidney function decline has expanded from glucose lowering in patients with type diabetes mellitus include CKD or without mellitus.1,2 Unfortunately, despite this expanding indication, many who qualify treatment an SGLT2 inhibitor do not receive drug. Low rates utilization are particularly evident among older CKD3,4 high failure and cardiovascular events patients. For instance, a Canadian registry...
Department of pharmacy, Free University Hospital, Amsterdam, *The Hague Hospitals Central Pharmacy and **Adult cystic fibrosis centre, The Hague, Netherlands.